Table 4.

Outcomes of Placebo-Controlled Trials of Pramlintide in Type 2 Diabetes

Trial, Duration	Change in HbA1c Level, %	PValue	Change in PPG, mg/dL	PValue	Change in Weight, kg	PValue
Riddle et al, 2007,9 16 wk
Pramlintide, 60 or 120 μg bid-tid	−0.70	<.05a	−24.4	<.001a	−1.6	<.001a
Placebo	−0.36		−0.4		+0.7
Ratner et al, 2002,8 52 wk
Pramlintide, 75 μg tid	−0.50	>.05a	NR		−0.5	<.001a
Pramlintide, 150 μg tid	−0.60	<.001a	NR		−1.4	<.001a
Placebo	−0.20		NR		+1.0
Hollander et al, 2003,6 52 wk
Pramlintide, 90 μg bid	−0.35		NR		−0.5
Pramlintide, 120 μg bid	−0.62	<.001b	NR		−1.25	<.003b
Placebo	−0.22		NR		+0.6

HbA_1c = glycated hemoglobin; bid = 2 times daily; NR = not reported; PPG = postprandial glucose; tid = 3 times daily.

^aCompared with placebo.

^bCompared with placebo for both dosages combined.